12,500 one-to-one meetings confirms value of partnering ‘in good times and bad’
All the indicators were up, including a markedly upbeat mood among the 2,500 participants, as BIO-Europe 2009 got underway in Vienna. Read more »
Cautious optimism for US biotech financing
The survivors from the Great Credit Crisis appear to be stronger companies and have learned to operate with less cash. Biotech dealmaking in the year ahead will be tough with more contingent/option-based transactions that aim to share risk and retain key employees. Read more »
Will US healthcare reform kill biotech innovation?
Even as market forces have made drug development a longer and more expensive process the reform of the American healthcare system promises to complicate that process further, creating a new world of uncertainty for biotech and pharma executives. Read more »
Dealmaking getting more creative
“We are not going to bother with how we got into the current situation but to ask what has changed,” said Denise Pollard-Knight as she opened the first plenary session at BIO-Europe 2009 entitled, ‘Rethinking the Drug Development Business Model.’ Read more »
2010 Dealmaking forecast: Partly cloudy
“We are looking at an earlier stage, seeking to move into innovative areas, which means entering into new sciences. It requires us to become less risk-adverse to develop differentiated medicines that will change treatment,” says Shelagh Wilson, head of GlaxoSmithKline’s newly created European Centre of Excellence for External Drug Discovery (CEED). Read more »
Science finally delivering break-throughs in oncology drug development
Participants crowded the aisles, sat on the floor and spilled out into the corridor to hear executives from Genentech and Abbott Molecular spell out requirements for new cancer drug programs. Read more »
BIO-Europe 2009′s glamorous receptions
Social networking has never been so glorious. The Schoenbrunn Palace’s Orangery, the imperial Redoute Halls at the Hofburg and the ballroom of Vienna’s town hall will be the setting for three events hosted by Life Science Austria Vienna Region (LISA VR) for participants at BIO-Europe 2009. Read more »
Medgenics: USD 7 million deal validates Biopump protein platform
One week ahead of BIO-Europe 2009, Medgenics announced its first preclinical development and option agreement with what it described as “a major international biopharmaceutical company that is a market leader in the field of hemophilia.” Read more »
Newsletter